Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

美罗华 医学 滤泡性淋巴瘤 维持疗法 内科学 肿瘤科 化疗 淋巴瘤
作者
Gilles Andre Salles,John Francis Seymour,Fritz C. Offner,Armando López‐Guillermo,David Belada,Luc Xerri,Pierre Feugier,Réda Bouabdallah,John Vincent Catalano,Pauline Brice,Dolores M. Caballero,Corinne Haïoun,Lars Møller Pedersen,Alain Jacques Delmer,David Simpson,Sirpa Leppä,Pierre Soubeyran,Anton Hagenbeek,Olivier Casasnovas,Tanin Intragumtornchai
出处
期刊:The Lancet [Elsevier BV]
卷期号:377 (9759): 42-51 被引量:1095
标识
DOI:10.1016/s0140-6736(10)62175-7
摘要

Background Patients with follicular lymphoma can have long survival times, but disease progression typically occurs 3–5 years after initial treatment. We assessed the potential benefit of 2 years of rituximab maintenance after first-line treatment in patients with follicular lymphoma receiving a rituximab plus chemotherapy regimen. Methods The randomised, open-label PRIMA study was undertaken in 223 centres in 25 countries. 1217 patients with previously untreated follicular lymphoma needing systemic therapy received one of three non-randomised immunochemotherapy induction regimens used in routine practice. 1019 patients achieving a complete or partial response were then randomly assigned to receive 2 years of rituximab maintenance therapy (375 mg/m2 every 8 weeks) or observation. Treatment was assigned equally by centralised block randomisation, stratified by induction regimen, response, region, and centre. Neither the participants nor those giving the interventions, assessing outcomes, and analysing data were masked to group assignments. The primary endpoint was progression-free survival (PFS). Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00140582. Findings 505 patients were assigned to rituximab maintenance and 513 to observation (one patient died during randomisation). With a median follow-up of 36 months (IQR 30–42), PFS was 74·9% (95% CI 70·9–78·9) in the rituximab maintenance group (130 patients progressed) and 57·6% (53·2–62·0) in the observation group (218 progressed; hazard ratio [HR] 0·55, 95% CI 0·44–0·68, p<0·0001). 2 years after randomisation, 361 patients (71·5%) in the rituximab maintenance group were in complete or unconfirmed complete response versus 268 (52·2%) in the observation group (p=0·0001). Overall survival did not differ significantly between groups (HR 0·87, 95% CI 0·51–1·47). Grade 3 and 4 adverse events were recorded in 121 patients (24%) in the rituximab maintenance group and 84 (17%) in the observation group (risk ratio 1·46, 95% CI 1·14–1·87; p=0·0026). Infections (grades 2–4) were the most common adverse event, occurring in 197 (39%) and 123 (24%) patients, respectively (risk ratio 1·62, 95% CI 1·35–1·96; p<0·0001). Interpretation 2 years of rituximab maintenance therapy after immunochemotherapy as first-line treatment for follicular lymphoma significantly improves PFS. Funding Groupe d'Etude des Lymphomes de l'Adulte (GELA) and F Hoffmann-La Roche.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
顺利的妖妖完成签到 ,获得积分10
刚刚
zys完成签到,获得积分10
刚刚
起点完成签到,获得积分10
1秒前
顺利毕业完成签到,获得积分10
1秒前
刘刘刘完成签到,获得积分10
1秒前
怡然梦玉完成签到 ,获得积分10
1秒前
小黎完成签到,获得积分10
2秒前
石大李克完成签到,获得积分10
2秒前
11完成签到 ,获得积分10
2秒前
xxxuiao发布了新的文献求助10
3秒前
xx发布了新的文献求助10
3秒前
老实的秋寒完成签到,获得积分10
3秒前
gujh完成签到,获得积分20
3秒前
狂炫砂糖柑完成签到,获得积分10
3秒前
超级寄文完成签到,获得积分10
3秒前
HuBasya发布了新的文献求助10
4秒前
平淡的初露完成签到 ,获得积分10
4秒前
4秒前
NexusExplorer的应助被xzq82457采纳,获得10
4秒前
群青完成签到,获得积分10
4秒前
你好完成签到,获得积分20
4秒前
领导范儿的应助被vv采纳,获得10
4秒前
阿赵完成签到,获得积分10
4秒前
6秒前
迷人葶完成签到,获得积分10
6秒前
花痴的发卡完成签到 ,获得积分10
6秒前
6秒前
广州队完成签到,获得积分0
6秒前
6秒前
细心的山槐完成签到,获得积分10
7秒前
仔仔完成签到 ,获得积分10
7秒前
雪碧和果冻完成签到,获得积分10
7秒前
7秒前
叉叉完成签到,获得积分10
8秒前
懒羊羊完成签到,获得积分10
8秒前
木棉花糖完成签到,获得积分10
8秒前
glacier完成签到,获得积分10
9秒前
飞飞完成签到,获得积分10
9秒前
天天向上的应助被LK8669090采纳,获得30
9秒前
欣喜的绝山完成签到 ,获得积分10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180275
求助须知:如何正确求助?哪些是违规求助? 9570366
关于积分的说明 21810725
捐赠科研通 7776380
什么是DOI,文献DOI怎么找? 3433277
关于科研通互助平台的介绍 2557483
邀请新用户注册赠送积分活动 2479042